新闻资讯
科思
/
/
/
Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

  • 分类:公司新闻
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:27
  • 访问量:

【概要描述】 To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

【概要描述】 To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

  • 分类:公司新闻
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:27
  • 访问量:
详情

  OBJECTIVE: To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

  METHODS: A cohort of 550 consecutive patients who underwent PCI for stable chest pain or acute coronary syndromes with implantation of at least one BVS (Absorb, Abbott Vascular) was systematically followed up by telephone interview and review of medical charts. Data on devicethrombosis were retrospectively analyzed in relationship to clinical and angiographic characteristics.

  RESULTS: Follow-up was achieved in 533 patients (97%, median follow-up 233 days). A total of 964 BVS were implanted in 645 vessels. In addition, 234 metal stents were implanted in 149 patients, including "hybrid intervention" with the combined use of BVS and stents in the same artery in 122 patients. Documented were 15 definite, 1 probable, and 8 possible cases of device thrombosis (rate of definite/probable devicethrombosis: 3.0%). Of these, 6 definite and 6 possible thromboses could be unambiguously attributed to BVS (1.1%), whereas a total of 11 definite, 1 probable, and 8 possible thromboses were potentially attributable to BVS (2.3%). Definite device thrombosis occurred in 7/122 patientswith "hybrid intervention" (5.7%).

  CONCLUSIONS: In a large real-world cohort treated with BVS, the rate of scaffold thrombosis was higher than published for randomized trials. A high rate of thrombosis was observed after combined implantation of BVS and stents within one vessel.

中国生物材料学会材料生物力学分会换届大会圆满召开
2022 12-08

中国生物材料学会材料生物力学分会换届大会圆满召开

精准植入 完美心舒——冠脉支架定位系统
2022 11-27

精准植入 完美心舒——冠脉支架定位系统

北京阿迈特与北京航空航天大学联合参与生物医疗器械国家急需高层次人才培养专项
2022 11-26

北京阿迈特与北京航空航天大学联合参与生物医疗器械国家急需高层次人才培养专项

公司信息

北京阿迈特医疗器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             邮箱:amt@ametcorp.com

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             

邮箱:amt@ametcorp.com